20:34 , Feb 23, 2018 |  BC Week In Review  |  Clinical News

Akari's Coversin meets in Phase II for PNH

Akari Therapeutics plc (NASDAQ:AKTX) said subcutaneous Coversin met the primary endpoint of reducing lactic dehydrogenase (LDH) to ≤1.8 times the upper limit of normal (ULN) at day 28 in the open-label Phase II COBALT trial...
23:38 , Oct 18, 2017 |  BC Innovations  |  Translation in Brief

Neutrophil bias

Researchers from the University of Texas Health Science Center have found that IL-27 promotes an anti-inflammatory phenotype in neutrophils that can treat stroke in mice. But safety issues around the recombinant cytokine have the team...
20:27 , Jun 23, 2017 |  BC Week In Review  |  Clinical News

RedHill begins second Phase III of RHB-105 to treat H. pylori infection

RedHill Biopharma Ltd. (Tel Aviv:RDHL; NASDAQ:RDHL) began the double-blind, U.S. Phase III ERADICATE Hp 2 trial to compare thrice-daily oral RHB-105 (Talicia) to equivalent doses of amoxicillin and omeprazole therapy in about 444 dyspepsia patients...
22:14 , Jan 12, 2017 |  BC Week In Review  |  Clinical News

SFX-01: Ph II SAS ongoing

An independent DSMB recommended continuation of the double-blind, placebo-controlled, U.K. Phase II SAS trial of SFX-01 given as capsules or as a suspension via a nasogastric tube based on an interim safety review. The trial...
07:00 , May 9, 2016 |  BC Week In Review  |  Clinical News

Sulforaphane: Phase II started

Evgen began the double-blind, placebo-controlled, U.K. Phase II SAS trial to evaluate 300 mg oral SFX-01 twice daily for up to 28 days plus nimodipine in about 90 patients. SFX-01 is administered as capsules or...
07:00 , Sep 28, 2015 |  BC Week In Review  |  Clinical News

PTVG-HP: Phase I/II started

Madison Vaccines began an open-label, U.S. Phase I/II trial to evaluate intradermal MVI-816 every 2 weeks for 6 doses with IV Keytruda pembrolizumab in about 32 patients. Patients will receive Keytruda every 3 weeks...
07:00 , Aug 24, 2015 |  BC Week In Review  |  Clinical News

OMS721: Phase II data

Data from 3 patients in the mid-dose cohort and 1 patient in the high-dose cohort of an open-label, international Phase II trial showed that OMS721 for 4 weeks was well tolerated. In the mid-dose cohort,...
00:51 , Aug 19, 2015 |  BC Extra  |  Top Story

Omeros soars on Phase II OMS721 data

Omeros Corp. (NASDAQ:OMER) jumped $10.48 (72%) to $25.03 on Tuesday after reporting data from four patients in an ongoing Phase II dose-escalation trial of OMS721 to treat thrombotic microangiopathies (TMAs) including atypical hemolytic uremic syndrome...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Financial News

InSphero completes venture financing

InSphero AG, Schlieren, Switzerland   Business: Supply/Service   Date completed: 2015-07-08   Type: Venture financing   Raised: CHF20 million ($21.3 million)   Investor: HP Wild Holding   ...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

RHB-105: Phase III data

Top-line data from the double-blind, placebo-controlled, U.S. Phase III ERADICATE Hp trial in 118 patients with confirmed H. pylori infection and non-investigated dyspepsia showed that thrice-daily oral RHB-105 for 14 days met the primary endpoint...